Brief: Compugen Reports FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701
01/06/2020 12:23
June 1 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR
PHASE
1/2 TRIPLE COMBINATION STUDY OF COM701 WITH BRISTOL MYERS
SQUIBB'S OPDIVO® (NIVOLUMAB) AND TIGIT INHIBITOR
* COMPUGEN - ON-TRACK TO BEGIN TRIPLE COMBINATION STUDY
DURING
SECOND HALF OF 2020
* COMPUGEN - COM701 TRIPLE COMBINATION STUDY TO EVALUATE
SIMULTANEOUS BLOCKADE OF PVRIG, TIGIT & PD-1 IMMUNE CHECKPOINTS
Source text for Eikon: ID:nPn9BJb82a
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025